Quick context
CJC-1295 with DAC
研究旨在延长生长激素和 IGF-1 信号；临床安全性尚未确立。
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Back to all 64 profiles
Community/research information only未获 FDA/EMA 批准WADA
Community protocol · CJC-1295 with DAC
CJC-1295 with DAC: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: CJC-1295 · CJC-1295 DAC · Drug Affinity Complex · GHRH analogue
Sources checked: 27 August 2026
重要安全与责任声明
本页记录并评估网络社区信息，不构成医疗或治疗建议、个体咨询，也不是使用邀请。
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Community/research information only
No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.
Amount status
Different amounts circulate online; no regulator-confirmed safe or effective dose exists.
Profile evidence level: early_human.
Timing
Community claims about time of day, fasting windows or training intervals are not validated clinical standards.
No individual recommendation.
Cycle/duration
Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community source复配与 U-100 换算
复配计算器
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
复配计算器
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
Long-acting growth hormone-releasing hormone analogue
CJC-1295 with DAC is classified as “Long-acting growth hormone-releasing hormone analogue”. 研究旨在延长生长激素和 IGF-1 信号；临床安全性尚未确立。 This describes the investigated pathway but does not validate a community use, amount, route or combination.
GHRH类似物
这项研究考察生长激素释放激素类似物是否促使垂体释放自身的生长激素,如同发出指令让腺体释放激素。研究人员测量血液中生长激素和IGF-1的水平。
生长激素释放
这项研究考察垂体在受到刺激后向血液中释放多少生长激素,类似于测量短暂打开水龙头后流出的水量。研究人员通常在多个时间点采血,以捕捉释放的量和时间规律。
生长轴放大
研究人员研究某物质如何放大从大脑到垂体再到生长激素的天然激素链,而不是直接补充生长激素。测量指标包括激素水平随时间的变化以及肌肉或脂肪量。
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
健身论坛
在这里,人们比较不同生长和修复肽之间的肌肉增长、力量提升和恢复时间,通常依据个人训练记录。商家和用户关于肌肉增长的说法属于个人经验之谈,而非对照研究结果。
抗衰老论坛
这里比较生长轴、线粒体和皮肤相关肽的组合方案,目的是影响可见或可感知的衰老迹象,通常经过多年个人记录。关于延缓衰老的轶事和商家广告并非科学证据。
来源与纯度讨论
人们讨论哪些商家被认为更值得信赖,以及不同批次之间纯度检测结果的差异。这类社区评估基于有限的样本,无法替代对每一批次进行的独立实验室检测。
Adverse effects and risk boundaries
- 干预GH、IGF-1或其他激素轴可能引起水肿、关节或神经不适、糖耐量异常以及血压和激素变化；许多研究物质缺乏可靠人体数据。
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- 活动性或既往肿瘤、未控制糖尿病、颅内疾病、妊娠/哺乳及激素敏感性疾病均需专科评估；获批产品有具体禁忌。
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- 在有医学依据的使用中，IGF-1、空腹血糖/HbA1c、血压、体重/水肿、甲状腺及适应证相关激素可能需要评估；这不是自行检测方案。
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
早期人体数据
临床数据有限;FDA列出的报告严重事件包括心率增快和全身性血管扩张反应。
Published evidence
已有一些早期、通常规模较小的人体研究或观察,但尚不能作为可靠的疗效证据。
含DAC的CJC-1295旨在延长作用时间,不同于不含DAC的短效版本。
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
未获 FDA/EMA 批准
没有 FDA 或 EMA 批准的药品；有效性与安全性尚未确立。
WADA 2026
This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceFDA: peptide compounding safety review
- Primary/technical sourceFDA warning letter: listed peptide substances
- Primary/technical sourceWADA — 2026 Prohibited List
- Community referenceCJC-1295 with DAC — Peptide Dosing Protocols